




IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION, CAN DEEP 
BRAIN STIMULATION OF THE SUBCALLOSAL CINGULATE GYRUS 
PROVIDE SYMPTOM RESOLUTION AS A REASONABLE ALTERNATIVE 




• MDD affects people of all ages, genders, and nationalities with a 
prevalence of 4.7% worldwide and 7% in the United States.1,2 
• Numerous treatment modalities for TRD exist including 
pharmacotherapy, psychotherapy, and electroconvulsive therapy, yet 
none are 100% guaranteed to relieve patient symptoms and improve 
overall quality of life.
• A new and emerging treatment option for TRD is DBS, an invasive 
procedure in which one or more electrodes are implanted into the 
brain through utilization of a stereotactic frame and magnetic 
resonance imaging. 
• The SCG is one of the main surgical targets for DBS in the treatment 
of TRD.
• It has been predicted that high frequency stimulation of the SCG via 
DBS could potentially reverse the pathological increased metabolic 
activity evident in depression.3
• Limited treatment options currently exist for patients with 
unrelenting major depressive symptoms that are refractory to 
antidepressant medication use or CBT. 
• While some studies have shown moderate benefit of DBS in the 
SCG, further studies are necessary to determine the overall efficacy 
and long term benefits of DBS as treatment for TRD.
• Although evidence exists that DBS may be an effective option for 
treating TRD, it is important to consider such therapy with caution, 
based on the individual patient, the severity of symptoms, and 
ultimately the patient’s quality of life. 
• It is presumed that DBS may serve as a probable option in patients in 
whom antidepressant medications and CBT have been ineffective for 
treating major depressive symptoms.
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To compare the efficacy of 
delayed onset DBS vs. non-
delayed DBS to improve 
patient depression scores. 
To determine the safety and 
efficacy of DBS in the 
treatment of chronic, 
unremitting TRD 
To confirm the efficacy of 
DBS in TRD; to determine 
the effect of withdrawing 




Protocols/   
Overview
RCT; immediate stimulation 
vs delayed stimulation. All 
participants received  active 
DBS after 4 weeks. 
Prospective, double blind, 
sham-controlled  RCT.  
Sham vs active stimulation 
lasted 6 months. At 6 
months, all participants 
received active stimulation
Randomized, double blind 
crossover study looking at 
relapse rates in patients who 
had already achieved 
remission with DBS. ON-
OFF vs OFF-ON 
Sample Size 8 90 5 
DBS 




HAMD-24 MADRS, GAF HAMD-17 
Follow Up
6 participants were followed 
for 28 months and 2 were 
followed for 4 years
All participants were 
followed for a total of 12 
months 
All participants were 





-4 weeks: No significance
found between delayed and 
immediate stimulation groups
-8 weeks: no significance seen
-12 mo: no significant 
decrease in scores
-24 mo: statistically
significant score reduction 
seen for all participants. No 
significance comparing 
delayed vs active group.
MADRS
-6 mo: no significance seen 
between groups
-12 mo: moderate reduction in 
scores seen in both groups, but 
overall not significant 
GAF
-6 and 12 mo: statistically 
significant improvement in 
depression and global 
functioning 
HAMD-17
-3, 6 mo: statistically 
significant difference in scores 
was observed at the end of both 
3 and 6 months comparing the 
ON groups to the OFF groups. 
KEY: DBS: deep brain stimulation; TRD: treatment resistant depression; SCG: subcallosal cingulate 
gyrus; MDD: major depressive disorder; HAMD: Hamilton depression rating scale; BDI: Becks 
Depression Inventory; MADRS: Montgomery–Åsberg Depression Rating Scale; GAF: Global Assessment 
Functioning
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Figure 2. Visualization of DBS lead placement within the subcallosal cortex 
(SCC).4 FOC: frontal orbital cortex. NAc: nucleus accumbens 
Figure 1. Location of electrode contacts on a sagittal view of the SCG 6,7
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